- Frontier IP said its portfolio company Exscientia entered into a drug-discovery partnership with GT Apeiron Therapeutics.

As part of the agreement, Exscientia would be entitled to become a shareholder in GT Apeiron as well as receiving milestones and royalties based on the clinical and commercial success of each programme.

GT Apeiron launched its biotechnology drug-discovery platform with US$27m backing from GT Healthcare, a life sciences-focused private equity partnership. GT Healthcare was also an investor in Exscientia.

At 8:51am: [LON:FIPP] Frontier IP Group PLC share price was +0.25p at 78.75p

Story provided by